InMed Pharmaceuticals (US: INM)

Last close As at 27/03/2024

0.37

−0.02 (−5.13%)

Market capitalisation

USD6m

Edison Investment Research is terminating coverage on InMed Pharmaceuticals. Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Previously published reports can still be accessed via our website.

Latest Insights

View More

Share Price Performance

Price Performance
% 1M 3M 12M
Actual 2.6 (49.4) (82.2)
Relative (8.3) (53.6) (81.7)
52 week high/low US$2.4/US$0.4

Financials

Edison Investment Research is terminating coverage on InMed Pharmaceuticals. Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Previously published reports can still be accessed via our website.

Y/E Jun Revenue (US$m) EBITDA (US$m) PBT (US$m) EPS (c) P/E (x) P/CF (x)
2020A 0.0 (9.0) (9.0) (172.80) N/A N/A
2021A 0.0 (9.8) (10.3) (153.02) N/A N/A
2022E 1.8 (14.6) (14.8) (97.62) N/A N/A
2023E 10.2 (13.2) (13.8) (63.67) N/A N/A

Thematics

thematic

Healthcare

Deutsches Eigenkapitalforum (EKF) 2023 healthcare

volition01

thematic

Healthcare

VolitionRx – Decoding the DNA of cancer 

thematic

Healthcare

ASCO 2023 key takeaways

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free